Analyst: On-chain prediction market fees are likely being underestimated; Kalshi's reported revenue of $110 million over the past 30 days is likely accurate.
Svmuu News: In response to Parity’s recently released ranking of prediction market revenues, crypto analyst dash posted on X, stating that Kalshi’s data is likely accurate. Based on its fee structure and publicly available taker transaction data, its fees amount to approximately $118 million. If transactions were conducted via Robinhood, a 1% nominal value estimate would be relatively accurate, with Kalshi’s nominal trading volume over the past 30 days reaching $11 billion. Additionally, fees for on-chain prediction markets are often underestimated. Currently, platforms like DefiLlama primarily track fees in USD or stablecoins, overlooking fees denominated in shares. When these fees are factored in, the actual fees for platforms such as Polymarket, predict.fun, and Limitless will be higher, with predict.fun being approximately 40% higher and Polymarket approximately 80% higher.
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
5
Iran-linked exchange Shelbit allegedly sent $676 million to Binance in sanctions-evasion operation, Reuters reports
-
6
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
7
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
8
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
-
9
Analysis: Vanguard Small-Cap Growth ETF (VBK) up 21% YTD 2026, Outperforming Large-Cap Growth ETF (VONG) at 0.3% YTD
-
10
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
Markets Today
Recommended Reading







